Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "IPA"

1726 News Found

Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I
R&D | March 29, 2026

Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I

The approval covers pediatric patients without a matched sibling donor for stem cell transplant


Shreehas Tambe appointed CEO & Managing Director of Biocon
People | March 28, 2026

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited


Eli Lilly drug shows 4-year relief for eczema patients, study finds
R&D | March 28, 2026

Eli Lilly drug shows 4-year relief for eczema patients, study finds

The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection


AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials
Clinical Trials | March 28, 2026

AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials

High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo


Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
Biotech | March 25, 2026

Earendil Labs bags $787m to supercharge AI-driven biologics pipeline

Capital infusion to accelerate Earendil’s R&D platform


Zydus launches affordable Semaglutide in India after patent expiry
News | March 23, 2026

Zydus launches affordable Semaglutide in India after patent expiry

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders


Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
R&D | March 23, 2026

Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026

Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses


AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051
Clinical Trials | March 23, 2026

AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention


Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes
News | March 21, 2026

Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes

The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India